Paris (France) and Cambridge (Massachusetts, U.S.), June 2, 2026, at 7:00 a.m. CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“百尔菲迪斯” or the “Company”), a pioneer in the development of transformative therapies targeting longevity, today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, bringing together diversified resources and expertise to jointly accelerate the development and commercialization of BIO101 in the Asian market.
BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…
